

References

E-17

1. DME MAC Jurisdiction A L5044. Effective 10/01/1993. Retired 09/30/2015.
2. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *LancetNeurol*. 2014;141-149.
3. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. *Parkinsonism and Related Disorders*. 2015;231-235.
4. Mateucci E, Giampietro O, Covalon V, et al. *Drug Design, Development and Therapy*. 2015;9:3109-3118.
5. Antonini A, Funch VSC, Boyd JT, et al. Effect of Levodopa-Carbidopa Intestinal Gel on Dyskinesia in Advanced Parkinson's Disease Patients. *Movement Disord*. 2016;530-536.
6. Noridian Healthcare Solutions, LLC. L33794. Effective 10/01/2015. Revised 01/01/2017.
7. Thrasher J, Bhargava A, Rees TM, Wang T, Guzman CB, Glass LC. Insulin Lispro with continuous subcutaneous insulin infusion is safe and effective in patients with type 2 diabetes: A randomized crossover trial of insulin Lispro vs insulin Aspart. *Endocr Pract*. 2015;21(3):247-57.